Our group recently reviewed the relevance of ABCB1 for CML patients, highlighting polymorphisms, associations with microRNAs and inhibitor of apoptosis proteins (IAPs) that relate to therapeutic resistance. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.